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Abstract
Background: Esophageal squamous cell carcinoma (SCC) represents one of the most malignant tumors. To
improve the poor prognosis, it is necessary to diagnose esophageal SCC at early stages using new tumor markers.
SEREX (serological identification of antigens by recombinant cDNA expression cloning) is suitable for large-scale
screening of tumor antigens and has been applied for various types of human tumors.
Methods: Tumor markers of esophageal squamous cell carcinoma (SCC) were screened by SEREX method. The
presence of serum anti-makorin 1 (MKRN1) antibodies (s-MKRN1-Abs) was examined by Western blotting using
bacterially expressed MKRN1 protein. The expression levels of MKRN1 mRNA in tissues were examined by RT-
PCR. The biological activity of MKRN1 was examined by transfection of ras-NIH3T3 mouse fibroblasts with
MKRN1 cDNA. Major ubiquitinated proteins in MKRN1-transfected cells were identified by immunoprecipitation
with anti-ubiquitin antibody followed by mass spectrometry.
Results: MKRN1 was identified as a novel SEREX antigen of esophageal SCC. Although a total of 18 (25%) of 73
patients with esophageal SCC had s-MKRN1-Abs, none of the 43 healthy donors had a detectable level of s-
MKRN1-Abs. There was no correlation between the presence of s-MKRN1-Abs and clinicopathological variables
other than histological grading. Well-differentiated tumors were associated significantly with the presence of s-
MKRN1-Abs in the patients. The mRNA levels of MKRN1 were frequently higher in esophageal SCC tissues than
in the peripheral normal esophageal mucosa. Stable transfection of ras-NIH3T3 cells with MKRN1 cDNA induced
prominent morphological changes such as enlargement of the cell body and spreading. Ubiquitination of 80- and
82-kDa proteins were clearly observed in MKRN1-transfected cells but not in the parental cells, which were
identified as L-FILIP (filamin A interacting protein 1).
Conclusion: MKRN1 is a novel SEREX antigen of esophageal SCC, and s-NKRN1-Abs can be a candidate of
diagnostic markers of esophageal SCC with high specificity. It is plausible that MKRN1 is involved in carcinogenesis
of the well-differentiated type of tumors possibly via ubiquitination of L-FILIP.
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Background
Esophageal squamous cell carcinoma (SCC) represents
one of the most malignant tumors [1,2]. The poor prog-
nosis of this tumor is attributed largely to a delay in diag-
nosis. Several tumor markers have been used for the
diagnosis of esophageal SCC [3-5]. However, to improve
the detection of esophageal SCC, new tumor markers are
necessary. It has been known for several decades that the
immune system is able to recognize tumor cells [6,7]. This
was developed by Sahin et al. to establish a new method
called SEREX (serological identification of antigens by
recombinant cDNA expression cloning), which involves
the immunoscreening of cDNA libraries prepared from
tumor specimens with autologous or allogeneic sera [8].
Since clones isolated by SEREX can be easily identified by
nucleotide sequencing, SEREX is suitable for large-scale
screening of tumor antigens. SEREX screening of several
different human tumor types has identified many novel
tumor antigens [9,10].
A previous application of the SEREX method to esopha-
geal cancer resulted in the identification of NY-ESO-1, a
cancer-testis antigen expressed in various cancer cells but
not in normal tissues [8]. SEREX analysis has also led to
the isolation of several antigens with known cancer relat-
edness, including a mutated version of the p53 tumor sup-
pressor protein, while the presence of antibodies to p53 in
serum was associated with poor prognosis in esophageal
cancer [11-13]. We applied the SEREX methodology to
esophageal SCC with the aim of adding to the catalogue
of defined immunogenic proteins in human cancer [14-
21]. In this study, we report that makorin1 (MKRN1) is a
new tumor antigen of esophageal SCC.
Methods
Human esophageal carcinoma cDNA library
This study was approved by the Ethic Committee of Chiba
University, Graduate School of Medicine. Collection of
tissues and sera was agreed upon by patients and healthy
donors, after provision of written, informed consent.
Recombinant DNA work was done with official permis-
sion and in accordance with the rules of the government
of Japan. The human esophageal SCC cell line, T.Tn, was
established in the Department of Clinical Molecular Biol-
ogy, Chiba University, Graduate School of Medicine
[22,23]. Total RNA was prepared from T.Tn cells by the
acid guanidinium thiocyanate-phenol-chloroform
method [24] and purified to poly(A)+RNA using Oligotex-
dT30 (Super) mRNA Purification Kit (Takara Biochemi-
cals, Kyoto, Japan) according to the manufacturer's
instructions. cDNA was ligated into EcoRI-XhoI site of the
λZAP II phage. The original library size was 1.8 × 106.
Sera of patients and healthy donors
Sera were obtained from 73 esophageal cancer patients
with various stages of disease progression, as well as from
16 breast, 16 gastric, and 16 colorectal cancer patients
prior to treatment. The patients with esophageal carci-
noma consisted of 66 men (82%) and 7 women (18%),
with a median age of 65 years (range 39 to 86 years). No
treatment-related death was observed in these patients.
They were pathologically classified according to the TNM/
UICC classification [25] using resected specimens. The
patients included 14 with stage I cancer, 21 with stage II,
27 with stage III, and 11 with stage IV cancer (Table 1). All
patients underwent R0 resection with extended lym-
phadenectomy. After surgery, they were followed until the
end of March 2006 or their deaths with clinical examina-
tions and imaging studies on a regular basis. The median
follow-up for survivors was 30 months. Each sample was
centrifuged at 3,000 g for 5 min and then frozen at -80°C
until use. Repeated thawing and freezing of samples was
avoided.
CEA, CYFRA21-1 and SCC-Ag assays
Serum CEA and CYFRA21-1 concentrations were meas-
ured with Enzymun-TEST CEA and Enzymun-TEST
CYFRA21-1 (Boehringer Mannheim, Mannheim, Ger-
many), respectively. SCC-Ag levels were measured in
serum with an immunoradiometric Assay kit (Dynabott,
Tokyo, Japan). The cutoff values for serum CEA,
CYFRA21-1, and SCC-Ag levels were 4.6 ng/ml, 2.57 ng/
ml and 1.5 ng/ml, respectively, in accordance with the
manufacturer's instructions. The specificity at these cut-off
values is 95%.
Immunological screening of the esophageal carcinoma cell 
antigens by SEREX
Esophageal carcinoma antigens were screened by SEREX
as previously published by Sahin et al. [8]. Escherichia coli
XL1-Blue MRF' was infected with λZAP II phage which
contained a cDNA library, and the expression of cDNA
was induced by blotting on nitrocellulose membranes
(NitroBind, Osmonics Inc., Minnetonka, MN), which had
been pretreated with 10 mM isopropyl β-D-thiogalactos-
ide (IPTG, Wako, Kyoto, Japan) for 30 min. The mem-
branes were then washed three times with TBS-T [20 mM
Tris-HCl (pH 7.5), 0.15 M NaCl and 0.05% Tween-20],
and blocking was performed by treatment with 1% pro-
tease-free bovine serum albumin (Wako) in TBS-T for 1 h.
The membranes were exposed in 1:2000-diluted serum
for 1 h. After washing with TBS-T three times, the mem-
branes were treated with 1:5000-diluted alkaline phos-
phatase-conjugated Fc fragment-specific goat anti-human
IgG and making it react for 1 h. Positive reactions were
detected by incubation in color development solution
[100 mM Tris-HCl (pH 9.5), 100 mM NaCl and 5 mM
MgCl2] containing 0.3 mg/ml of nitroblue tetrazolium
chloride (Wako) and 0.15 mg/ml of 5-bromo-4-chloro-3-
indolyl-phosphate (Wako). Positive clones were recloned
twice to obtain monoclonality and retested for serum
reactivity.BMC Cancer 2009, 9:232 http://www.biomedcentral.com/1471-2407/9/232
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Table 1: Relationship between s-MKRN1-Abs and the clinicopathological variables in 73 patients with esophageal SCC
s-MKRN1-Abs
Positive Negative
(18 patients) (55 patients)
Characteristics n (%) n (%) P value
Age
Median 65 yrs
Range 39–86 yrs
Under 59 yrs 6 (33) 21 (38)
Over 60 yrs 12 (67) 34 (62) 0.711
Sex Male 16 (89) 50 (91)
Female 2 (11) 5 (9) 0.555
Location Ce 0 (0) 4 (7)
Ut 4 (22) 7 (13)
Mt 9 (50) 29 (53)
Lt 4 (22) 9 (16)
Ae 1 (6) 4 (7)
Unknown 0 (0) 2 (4) 0.682
Tumor size
Median 58.6 mm
Range 15–140 mm
Under 29 mm 2 (11) 8 (15)
Over 30 mm 13 (72) 47 (85)
Unknown 3 (17) 0 (0) 0.636
Histopathological Grading GX 8 (44) 20 (37)
G1 6 (33) 5 (9)
G2 4 (22) 21 (38)
G3 0 (0) 9 (16) 0.008
Primary Tumor Tis 0 (0) 1 (2)
T1 3 (17) 16 (29)
T2 4 (22) 10 (18)
T3 5 (28) 13 (24)
T4 6 (33) 15 (27) 0.824
Regional Lymph Nodes N0 3 (17) 17 (31)
N1 15 (83) 38 (69) 0.194
Distant Metastasis M0 16 (89) 46 (84)
M1 2 (11) 9 (16) 0.455
Stage Grouping Stage 0 0 (0) 1 (2)
Stage I 1 (6) 12 (22)
Stage IIA 1 (6) 3 (5)
Stage IIB 6 (33) 11 (20)
Stage III 8 (44) 19 (35)
Stage IV 2 (11) 9 (16) 0.552
Tumor Markers
SCC-Ag Positive 7 (39) 19 (35)
Negative 11 (61) 32 (58)
ND 0 (0) 4 (7) 0.902BMC Cancer 2009, 9:232 http://www.biomedcentral.com/1471-2407/9/232
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Sequence analysis of identified antigens
Monoclonalized phage cDNA clones were converted to
pBluescript phagemid by in vivo excision using the ExAs-
sist helper phage (Stratagene, La Jolla, CA). Plasmid DNA
was obtained from Escherichia coli SOLR strain trans-
formed by the phagemid. The cDNA inserts were
sequenced by the dideoxy chain termination method
using the DNA Sequencing kit BigDyeTM Terminator
(Applied Biosystems, Foster City, CA) and ABI PRISM
3700 DNA Analyzer (Applied Biosystems). Sequences
were analyzed for homology with public databases of
known genes and proteins using NCBI-BLAST.
Western blotting analysis
Escherichia coli JM109 cells which contained cDNA clones
recombined in pBluescript II were cultured with or with-
out 0.1 mM IPTG for 2.5 h. Cells were then washed with
phsphate-buffered saline and lysed by incubation at
100°C for 3 min in SDS sample buffer [26]. Escherichia coli
lysate was then subjected to SDS-PAGE followed by west-
ern blotting using sera of 73 patients with esophageal can-
cer, 14 with breast cancer, 9 with gastric cancer, and 16
with colorectal cancer.
Statistical analyses
The chi-square test or Fisher exact test (2-sided) was per-
formed. The survival probabilities were calculated using
the product-limit method of Kaplan and Meier, consider-
ing all deaths. Survival differences between groups were
determined using the log-rank test. Fisher's exact proba-
bility test was used to determine the significance of the
differences between two groups. All statistical analyses
were carried out using the Stat View 5.0 program for Win-
dows (SAS Institute Inc., Cary, NC). P values at the 0.05
level were considered statistically significant.
Reverse transcription-PCR (RT-PCR)
Total cellular RNA was isolated from the T.Tn esophageal
SCC cell line using AquaPure RNA Isolation Kit (Bio-Rad,
Hercules, CA), or from the tumor tissues using FastPure
RNA Kit (Takara Bio, Otsu, Japan). RNA of normal
esophageal keratinocytes was purchased from Cybrdi
(Frederick, MD). Reverse transcription was performed
with an oligo(dT)20 primer using the ThermoScript RT-
PCR System (Invitrogen). The presence of MKRN1 tran-
scripts was examined via PCR amplification using the fol-
lowing primers: sense, 5'-AACGGGTGCCTCAGTG
TCCTT-3'; antisense, 5'-CTCCTGATGTTGTGGCTGTTG-
3'. β-actin-specific PCR primers (sense, 5'-ACCACAGCT-
GAGAGGGAAATC-3'; antisense, 5'-AGCACTGTGTT-
GGCATAGAGG-3') were used as a loading control. PCR
was performed using KOD-Plus-DNA polymerase (Toy-
obo, Osaka, Japan) as follows: an initial denaturation step
at 94°C for 3 min, followed by 33 cycles for MKRN1 or 25
cycles for β-actin of denaturation at 94°C for 15 sec,
annealing at 60°C for 30 sec, and extension at 68°C for
30 sec, with a final extension of 5 min at 68°C.
Isolation of stable transfectants
Activated Ha-ras-transformed NIH3T3 mouse fibroblasts
(clone F25) (ras-NIH3T3) [27,28] were cultured in Dul-
becco's modified Eagle's medium (Nissui Pharmaceutical,
Tokyo, Japan) supplemented with 5% heat-inactivated
bovine serum. Eukaryotic expression vector pME18S-FL3
containing human MKRN1 cDNA was purchased from
Toyobo (Osaka, Japan). ras-NIH3T3 cells (5 × 104 cells)
were co-transfected with MKRN1 cDNA and neo  gene
using Lipofectamine reagent (Invitrogen) as described
[28,29]. After culture in the presence of G418 (400 μg/ml)
for two weeks, surviving colonies were isolated.
Peptide synthesis and generation of polyclonal antibodies
Two peptides consisting of amino acids between 104 and
118 (CRYEHSKPLKQEEAT) and of amino acids between
399 and 412 (EPQRQKVGTSSRYR) from the MKRN1 pro-
tein were synthesized and called MKRN1-K1 and K2,
respectively. The peptide was coupled to keyhole limpet
haemocyamine that had been activated with N-succinim-
idyl-3-maleinimido-proprionate. To obtain antibodies,
rabbits (bastards) were immunized by subcutaneous
injections of 300 μg of coupled peptide emulsified in Fre-
und's complete adjuvant. The immunization was repeated
twice at 2-week intervals with the same amount of cou-
pled peptide in Freund's incomplete adjuvant. The titer
was tested after each bleed by enzyme-linked immuno-
sorbent assay (ELISA).
Peptide-specific antibodies were enriched by using the
pretested rabbit serum columns (Amersham Biosciences,
Piscataway, NJ) according to the manufacturer's instruc-
CYFRA21-1 Positive 3 (17) 13 (24)
Negative 15 (83) 38 (69)
ND 0 (0) 4 (7) 0.340
CEA Positive 2 (11) 12 (22)
Negative 16 (89) 37 (67)
ND 0 (0) 6 (11) 0.199
Table 1: Relationship between s-MKRN1-Abs and the clinicopathological variables in 73 patients with esophageal SCC (Continued)BMC Cancer 2009, 9:232 http://www.biomedcentral.com/1471-2407/9/232
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tions. In brief, 6 mg of the MKRN1 peptide were coupled
to the NHS-activated Sepharose column. Six ml of the rab-
bit serum were diluted 1:10 with 10 mM Tris-HCl (pH
7.5) and the diluted serum was applied twice to the equil-
ibrated column. Antibodies were eluted with 100 mM gly-
cine buffer (pH 2.5). Fractions were immediately
neutralized with 1 M Tris-HCl (pH 8.0). The final concen-
tration of the purified serum was 1:1.83.
Peptide mass fingerprinting
Extracts of MKRN1-transfected ras-NIH3T3 cells were
immunoprecipitated with anti-ubiquitin antibody (Santa
Cruz) followed by SDS-polyacrylamide gel electrophore-
sis as described previously [30]. The gel was stained with
silver (Invitrogen) and the gel pieces containing 80- and
82-kDa proteins were washed with water and dehydrated
with acetonitrile. After removing acetonitrile, the gel piece
was dried in a vacuum centrifuge, supplied with 10 mM
dithiothreitol in 100 mM ammonium bicarbonate, and
incubated for 1 h at 56°C. The solution was replaced by
the same volume of 55 mM iodoacetamide in 100 mM
ammonium bicarbonate and incubated for 45 min at
room temperature in the dark. The gel piece was washed
with 100 mM ammonium bicarbonate, dehydrated with
acetonitrile, rehydrated with 100 mM ammonium bicar-
bonate, dehydrated again with acetonitrile, and dried in a
vacuum centrifuge following elimination of acetonitrile.
The dried gel piece was immersed in trypsin solution con-
taining 10 μg/ml trypsin in 50 mM ammonium bicarbo-
nate and 5 mM calcium chloride, incubated for 45 min at
4°C, and further at 37°C for 12 h. Peptides were extracted
using sequential steps of 20 mM ammonium bicarbonate,
followed by 5% formic acid in 50% acetonitrile. The
extract was dried in a vacuum centrifuge, supplied with
0.1% trifluoroacetic acid and desalted using ZipTip C18
(Millipore) according to the manufacturer's protocol. The
peptides were eluted with 0.1% trifluoroacetic acid in
50% acetonitrile and applied onto MALDI plate.
Mass spectrometry
Mass spectrometry of peptides was performed using
MALDI-TOF MS AXIMA-CFR (Shimadzu Corporation,
Tsukuba, Japan). Protein identification was performed
using Mascot search (Matrix Science, http://www.matrix
science.com/).
Results
Serological screening of T.Tn cell cDNA library
A total of approximately 2 × 107 pfu from the T.Tn cDNA
library were screened using serum samples derived from
21 patients with esophageal SCC. One of the isolated
clones, 15J1-3, showed strong homology with the
makorin1 (MKRN1; NCBI accession number:
NM_013446) gene. MKRN1 appeared to be of much
interest because its expression is much higher in the brain
and testis than other tissues [31]. A recent report revealed
that MKRN1 is involved in the differentiation of various
tissues including osteoblasts, eye epithelial cells and kid-
ney [32].
Immune recognition of MKRN1 gene product in patients 
with eophageal SCC
The existence of antibodies against the MKRN1 gene prod-
uct was examined with 73 sera of patients with esophageal
SCC and 43 sera of healthy donors by Western blot anal-
ysis. In order to confirm that the antigen reacting with
serum antibodies derives from the insert cDNA, protein
extracts of IPTG-treated Escherichia coli bearing MKRN1
cDNA expression plasmids or the control empty plasmids
were compared with those of non-treated bacteria. The
50-kDa band which appeared only in MKRN1-expressing
bacteria in response to IPTG was judged as positive. Figure
1 shows the representative results of s-MKRN1-Abs-nega-
tive serum of a healthy donor, #1, and s-MKRN1-Abs-pos-
itive serum of a patient, #15. For this 50-kDa band, 18 of
73 (25%) sera of patients with esophageal SCC were sero-
positive (data not shown). In contrast, all 43 healthy
donors were sero-negative. Similarly, positive bands were
detected in the sera of two of 14 (14%) breast cancer
patients, none of the 9 (0%) gastric cancer patients and six
of the 16 (38%) colon cancer patients (data not shown).
Presence of serum anti-MKRN1 antibodies and 
clinicopathological variables of esophageal SCC
We then examined the relationship between the presence
of s-MKRN1-Abs and the clinicopathological features of
the patients (Table 1). As for histopathological grading,
well-differentiated tumors (G1) were associated with the
presence of s-MKRN1-Abs significantly compared to
poorly differentiated tumors (G3), and vice versa (P  =
0.008). Nodal involvement was more frequently observed
in the patients with s-MKRN1-Abs than in those without
s-MKRN1-Abs, yet the difference was not statistically sig-
nificant (P = 0.194). There was no correlation between the
presence of s-MKRN1-Abs and other features such as age,
gender, location, tumor sizes, depth of tumor, distant
metastasis and stages. Kaplan-Meier plotting showed no
significant correlation between s- MKRN1-Abs and sur-
vival (Figure 2).
Correlation between the presence of s-MKRN1-Abs and 
positivity of conventional serum tumor markers
When the patients were divided into two groups accord-
ing to the presence of s-MKRN1-Abs, there was no signifi-
cant correlation between the presence of s-MKRN1-Abs
and the positivity of conventional serum tumor markers
(Table 1). Consequently, the sensitivity of serum markers
to detect esophageal SCC was improved by using s-
MKRN1-Abs in combination with conventional markers.
For example, the positivity increased from 36% of SCC-AgBMC Cancer 2009, 9:232 http://www.biomedcentral.com/1471-2407/9/232
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alone to 51 % by combination of s-MKRN1-Abs and SCC-
Ag.
Increased expression of MKRN1 mRNA in esophageal SCC
The expression levels of MKRN1 mRNA in esophageal tis-
sue specimens of SCC or normal cells were examined by
RT-PCR analysis. T.Tn esophageal SCC cells, as a positive
control, showed higher MKRN1 mRNA levels than nor-
mal esophageal keratinocytes (Figure 3). MKRN1 mRNA
levels in carcinoma tissues were higher than those in the
normal counterparts of patient numbers 2, 6, 7, 8 and 10.
Thus, this elevated expression may account for the devel-
opment of s-MKRN1-Abs.
Ubiquitination of L-FILIP was stimulated by MKRN1
To examine the biological role of MKRN1, human
MKRN1 cDNA was recombined in pcDNA3-Myc, His and
transfected into ras-NIH3T3 cells as described [28]. The
protein (Figure 4a) and mRNA (Figure 4b) of transduced
MKRN1 were observed in a stable transfected clone,
Fmkrn-24, but not in the parental ras-NIH3T3 cells. The
phase morphology of Fmkrn-24 was markedly different
from the parental cells; i.e. enlargement of cell bodies
with flat and extended cell periphery (Figure 4c). Because
E3 ubiquitin-protein ligase activity was suspected to
MKRN1 [31,33], ubiquitinated proteins were examined
by Western blotting using anti-ubiquitin antibody. Two
ubiquitinated proteins of 80 and 82 kDa were clearly
observed in two MKRN1 transfectants but not in the
parental ras-NIH3T3 cells (Figure 4a). These two proteins
in Fmkrn-24 cells were immunoprecipitated with anti-
ubiquitin antibody, separated by SDS-polyacrylamide gel
electrophoresis and analyzed by mass spectrometry. Six
tryptic polypeptides were completely matched to the
sequence of mouse L-FILIP (filamin A interacting protein
1) (Figure 5). This suggests that the ubiquitination of L-
FILIP was induced by MKRN1.
Discussion
In the current study, we applied SEREX analysis to esopha-
geal SCC, and identified MKRN1. MKRN1 locus maps to
a conserved syntenic group near the T-cell receptor cluster
in chromosome 7q34 [31]. MKRN1 is widely expressed in
mammals at high levels in the murine embryonic nervous
system and adult testis. Thus far, several MKRN1-related
genes have been reported, and MKRN1 is the ancestral
founder of the MKRN1 gene family. This family encodes
putative ribonucleoproteins with a distinct collection of
four zinc-finger motifs followed by a RING zinc-finger
[31]. E3 ubiquitin-protein ligase activity is intrinsic to
RING domain-containing molecules such as Mdm2 and c-
Cbl. Kim et al. have shown that MKRN1 binds and pro-
motes ubiquitination of TERT and subsequent proteaso-
mal degradation [33]. On the other hand, Hirotsune et al.
have reported that a putative pseudogene-induced desta-
bilization of MKRN1 led to defects of differentiation such
as polycystic kidneys and bone deformity [32].
The presence of serum MKRN1 antibodies (s-MKRN1-
Abs) in cancer patients was examined by Western blotting
(Figure 1). s-MKRN1-Abs were frequently observed in
patients with esophageal SCC (25%) and colon carci-
noma (38%) but not in healthy donors. Even in patients
with early-stage (T1) esophageal tumors, s-MKRN1-Abs
were positive for 3 (16%) of 19 patients (Table 1). Thus,
s-MKRN1-Abs can be a candidate of diagnostic markers of
esophageal SCC with low false positive rates.
There was no correlation between the presence of s-
MKRN1-Abs and clinicopathological variables except his-
tological grading (Table 1). Well-differentiated type
tumors were observed more frequently in the patients
with s-MKRN1-Abs than in the patients without s-
MKRN1-Abs. This is consistent with the report of Hirot-
sune et al. that MKRN1 has a crucial role in differentiation
[32].
Recognition of MKRN1 by serum antibodies in patients with  esophageal SCC Figure 1
Recognition of MKRN1 by serum antibodies in 
patients with esophageal SCC. Escherichia coli containing 
MKRN1 cDNA expression plasmid (MKRN1) or control 
empty plasmid (Control) was treated with (+) or without (-) 
IPTG for 2.5 h, and cell lysates were subsequently subjected 
to Western blot analysis using the sera from healthy donor 
#1 and esophageal SCC patients #15 as indicated. An arrow 
indicates the IPTG-induced polypeptide that represents the 
encoded MKRN1 cDNA product.
Plasmid: Control  MKRN1  Control  MKRN1
IPTG:        -     +     -     +       -    +     -    +
Serum from a
patient (#15) with
esophageal SCC
Serum from a
healthy donor
(#1)
25 kDa-
32.5 kDa-
47.5 kDa-
62 kDa-BMC Cancer 2009, 9:232 http://www.biomedcentral.com/1471-2407/9/232
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RT-PCR analysis showed that the expression of MKRN1
mRNA was frequently higher in esophageal SCC tissues
than in the peripheral normal esophageal mucosa (Figure
3). Densitometric analysis revealed that the relative
expression levels of MKRN1 versus β-actin mRNA in
esophageal SCC were approximately 2.5-fold higher than
in the normal esophageal mucosa. This elevated expres-
sion may, in part, account for the development of serum
antibodies, and give a rationale of application of s-
MKRN1-Abs as a tumor marker.
Stable transfection of ras-NIH3T3 cells with MKRN1
cDNA showed prominent morphological changes (Figure
4), which resembled phenotypic reversion of ras-NIH3T3
cells to NIH3T3-like cells [34]. This suggests an effect of
MKRN1 on actin cytoskeleton because such changes were
frequently associated with reorganization of actin stress
fibers [35]. In addition, ubiquitination of 80- and 82-kDa
proteins was induced by transfection with two MKRN1-
transfected cells (Figure 4a). Mass spectrometry revealed
that these ubiquitinated proteins are L-FILIP (Figure 5).
FILIP interacts with filamin A, a component of stress fib-
ers, and induces degradation of filamin A, leading to alter-
Kaplan-Meier overall survival curves for the patients with or  without s-MKRN1-Abs Figure 2
Kaplan-Meier overall survival curves for the patients 
with or without s-MKRN1-Abs. Logrank (Mantel-Cox) P-
value = 0.5209.
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Elevated levels of MKRN1 mRNA in esophageal SCC tissues Figure 3
Elevated levels of MKRN1 mRNA in esophageal SCC 
tissues. MKRN1 (upper panel) and β-actin (lower panel) 
mRNA levels were examined by RT-PCR in specimens of 
normal (N) and carcinoma (T) tissues resected from patients 
1 to 10 (#1 – #10). 'Normal keratinocyte' and 'T.Tn' repre-
sent the products from RNA of normal esophageal keratino-
cytes obtained from Cybrdi and the T.Tn esophageal SCC 
cell line, respectively.
Normal keratinocyte
T.Tn              #1      #2      #3      #4       #5       #6      #7       #8      #9       #10
           N   T   N  T   N  T   N   T   N  T     N  T   N   T   N   T   N   T   N   T
-actin
MKRN1
Isolation of stable MKRN1 transfectants Figure 4
Isolation of stable MKRN1 transfectants. (a) Protein 
expression levels of MKRN1, His-tagged proteins, ubiquiti-
nated proteins and β-actin in MKRN1 transfectants, Fmkrn-
24 and 21, and the parental ras-NIH3T3 cells were examined 
by Western blotting using the anti-MKRN1 peptide antibody, 
the anti-His antibody (lower panel), the anti-ubiquitin anti-
body or the anti-β-actin antibody. (b) Expression of MKRN1 
mRNA in MKRN1 transfectant Fmkrn-24 and ras-NIH3T3 
cells was examined by RT-PCR. MKRN1 sequence between 
nucleotide positions 29 and 536 was amplified. The position 
of PCR products is indicated by an arrow. (c) Phase mor-
phology of ras-NIH3T3 and Fmkrn-24 cells. Original magnifi-
cation, ×100.
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ation of cell shape and decrease in cell motility [36,37].
Therefore, MKRN1-induced ubiquitination of L-FILIP fol-
lowed by degradation with proteasome system may
explain the prominent morphological changes in
MKRN1-transfected cells as well as the effects on differen-
tiation.
The expression of MKRN1 is increased in half (5 out of 10
cases) but not all esophageal SCC tissues (Figure 3).
Therefore, it is implausible that MKRN1 has an indispen-
sable role in esophageal carcinogenesis. However,
involvement in differentiation and the effects on the
cytoskeleton via L-FILIP suggest that MKRN1 has a key
role in a certain type of esophageal carcinogenesis. Sup-
pression of MKRN1 activity might be a novel strategy for
esophageal SCC therapy.
Conclusion
It is plausible that MKRN1 is involved in differentiation
and carcinogenesis of a certain type of esophageal SCC. s-
MKRN1-Abs can be a candidate of diagnostic markers of
esophageal SCC.
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